Polymorphism of CD14 Gene Is Associated with Adverse Outcome among Patients Suffering from Cardiovascular Disease

Susanne Schulz, Martin Zielske, Sascha Schneider, Britt Hofmann, Hans-Günter Schaller, Axel Schlitt, Stefan Reichert, Susanne Schulz, Martin Zielske, Sascha Schneider, Britt Hofmann, Hans-Günter Schaller, Axel Schlitt, Stefan Reichert

Abstract

Background: The biological link between severe periodontitis and cardiovascular disease is well established. Both complex inflammatory diseases are influenced by genetic background. Therefore, the impact of genetic variations of receptors of the innate immune system-(Toll-like receptors (TLRs)) TLR2, TLR4, cluster of differentiation 14 (CD14), and the transcription factor nuclear factor-κΒ (NF-κB)-was investigated.

Materials and methods: In this study (ClinicalTrials.gov identifier: NCT01045070), 1002 cardiovascular (CV) patients were included. In a 3-year follow-up period, new vascular events were assessed. SNPs in CD14 (rs2569190), NF-κΒ (rs28362491), TLR2 (rs5743708), and TLR4 (rs4986790) were genotyped. The impact of these genetic variants on severe periodontitis as well as on CV outcome was assessed.

Results: All investigated genetic variants were not associated with preexisting CV events or severe periodontitis in CV patients. In Kaplan-Meier survival analyses, the CT genotype of CD14 single-nucleotide polymorphism (SNP) rs2569190 was shown to be an independent predictor for combined CV endpoint (log rank: p = 0.035; cox regression; hazard ratio: 1.572; p = 0.044) as well as cardiovascular death (log rank: p = 0.019; cox regression; hazard ratio: 1.585; p = 0.040) after three years of follow-up.

Conclusions: SNPs in CD14, NF-κΒ, TLR2, and TLR4 are no risk modulators for preexisting CV events or severe periodontitis in CV patients. The CT genotype of CD14 SNP rs2569190 provides prognostic value for further CV events within 3 years of follow-up.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Copyright © 2021 Susanne Schulz et al.

Figures

Figure 1
Figure 1
Kaplan-Meier plot for the incidence of the (a) combined endpoint (stroke/TIA, myocardial infarction, cardiovascular death, and death from stroke) and (b) cardiovascular death within a 3-year follow-up period according genotype distribution of CD14 SNP rs2569190. Statistical comparison was made by the log-rank test.

References

    1. Lucas K., Maers M. Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Molecular Neurobiology. 2013;48(1):190–204. doi: 10.1007/s12035-013-8425-7.
    1. Pinheiro C. R., Coelho A. L., de Oliveira C. E., et al. Recognition of Candida albicans by gingival fibroblasts: the role of TLR2, TLR4/CD14, and MyD88. Cytokine. 2018;106:67–75. doi: 10.1016/j.cyto.2017.10.013.
    1. Jaén R. I., Val-Blasco A., Prieto P., et al. Innate immune receptors, key actors in cardiovascular diseases. JACC: Basic to Translational Science. 2020;5(7):735–749. doi: 10.1016/j.jacbts.2020.03.015.
    1. Zacarias J. M. V., de Alencar J. B., Tsuneto P. Y., et al. The influence of TLR4, CD14, OPG, and RANKL polymorphisms in periodontitis: a case-control study. Mediators of Inflammation. 2019;2019:10. doi: 10.1155/2019/4029217.4029217
    1. Matucci A., Maggi E., Vultaggio A. Cellular and humoral immune responses during tuberculosis infection: useful knowledge in the era of biological agents. The Journal of Rheumatology. Supplement. 2014;91:17–23. doi: 10.3899/jrheum.140098.
    1. Song B., Zhang Y. L., Chen L. J., et al. The role of Toll-like receptors in periodontitis. Oral Diseases. 2017;23(2):168–180. doi: 10.1111/odi.12468.
    1. Sanz M., Marco Del Castillo A., Jepsen S., et al. Periodontitis and cardiovascular diseases: consensus report. Journal of Clinical Periodontology. 2020;47(3):268–288. doi: 10.1111/jcpe.13189.
    1. Aarabi G., Zeller T., Seedorf H., et al. Genetic susceptibility contributing to periodontal and cardiovascular disease. Journal of Dental Research. 2017;96(6):610–617. doi: 10.1177/0022034517699786.
    1. LeVan T. D., Bloom J. W., Bailey T. J., et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. Journal of Immunology. 2001;167(10):5838–5844. doi: 10.4049/jimmunol.167.10.5838.
    1. Arbour N. C., Lorenz E., Schutte B. C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nature Genetics. 2000;25(2):187–191. doi: 10.1038/76048.
    1. Schmitt C., Humeny A., Becker C. M., Brune K., Pahl A. Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clinical Chemistry. 2002;48(10):1661–1667. doi: 10.1093/clinchem/48.10.1661.
    1. Agnese D. M., Calvano J. E., Hahm S. J., et al. Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. The Journal of Infectious Diseases. 2002;186(10):1522–1525. doi: 10.1086/344893.
    1. Schroder N. W., Hermann C., Hamann L., Gobel U. B., Hartung T., Schumann R. R. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. Journal of Molecular Medicine. 2003;81(6):368–372. doi: 10.1007/s00109-003-0443-x.
    1. Wang Y., Wu B., Zhang M., Miao H., Sun J. Significant association between rs28362491 polymorphism in NF-κB1 gene and coronary artery disease: a meta-analysis. BMC Cardiovascular Disorders. 2020;20(1):p. 278. doi: 10.1186/s12872-020-01568-0.
    1. Chen C., Fan X., Yu S., et al. Association between periodontitis and gene polymorphisms of hBD-1 and CD14: a meta-analysis. Archives of Oral Biology. 2019;104:141–149. doi: 10.1016/j.archoralbio.2019.05.029.
    1. Xu J. J., Liu K. Q., Ying Z. M., et al. Effect of CD14 polymorphisms on the risk of cardiovascular disease: evidence from a meta-analysis. Lipids in Health and Disease. 2019;18(1):p. 74. doi: 10.1186/s12944-019-1018-3.
    1. Han M. X., Ding C., Kyung H. M. Genetic polymorphisms in pattern recognition receptors and risk of periodontitis: evidence based on 12,793 subjects. Human Immunology. 2015;76(7):496–504. doi: 10.1016/j.humimm.2015.06.006.
    1. Schulz S., Hierse L., Altermann W., et al. The del/del genotype of the nuclear factor-kappaB -94ATTG polymorphism and its relation to aggressive periodontitis. Journal of Periodontal Research. 2010;45(3):396–403. doi: 10.1111/j.1600-0765.2009.01251.x.
    1. Toker H., Görgün E. P., Korkmaz E. M. Analysis of IL-6, IL-10 and NF-κB gene polymorphisms in aggressive and chronic periodontitis. Central European Journal of Public Health. 2017;25(2):157–162. doi: 10.21101/cejph.a4656.
    1. Shan C., Aisaiti A., Wu Z. P., Wang T. T., Zhao J. Association of TLR-2 gene polymorphisms with the risk of periodontitis: a meta-analysis. Disease Markers. 2020;69353958
    1. Golovkin A. S., Ponasenko A. V., Yuzhalin A. E., et al. An association between single nucleotide polymorphisms within _TLR_ and _TREM-1_ genes and infective endocarditis. Cytokine. 2015;71(1):16–21. doi: 10.1016/j.cyto.2014.08.001.
    1. Jin S. H., Guan X. Y., Liang W. H., Bai G. H., Liu J. G. TLR4 polymorphism and periodontitis susceptibility: a meta-analysis. Medicine (Baltimore) 2016;95(36, article e4845) doi: 10.1097/MD.0000000000004845.
    1. Chen R., Gu N., Gao Y., Cen W. TLR4 Asp299Gly (rs4986790) polymorphism and coronary artery disease: a meta-analysis. PeerJ. 2015;26(3, article e1412)
    1. Schulz S., Lüdike H., Lierath M., et al. C-reactive protein levels and genetic variants of CRP as prognostic markers for combined cardiovascular endpoint (cardiovascular death, death from stroke, myocardial infarction, and stroke/TIA) Cytokine. 2016;88:71–76. doi: 10.1016/j.cyto.2016.08.021.
    1. Tonetti M. S., Claffey N. European Workshop in Periodontology group C, advances in the progression of periodontitis and proposal of definitions of a periodontitis case and disease progression for use in risk factor research. Group C consensus report of the 5th European Workshop in Periodontology. Journal of Clinical Periodontology. 2005;32:210–213.
    1. Ishaan D., Parthasarathy H., Ponnaiyan D., Tadepalli A. TheCD14 rs2569190 TT genotype is associated with chronic periodontitis. Genetic Testing and Molecular Biomarkers. 2017;21(9):560–564. doi: 10.1089/gtmb.2017.0029.
    1. Folwaczny M., Glas J., Török H. P., Fricke K., Folwaczny C. The CD14 -159C-to-T promoter polymorphism in periodontal disease. Journal of Clinical Periodontology. 2004;31(11):991–995. doi: 10.1111/j.1600-051X.2004.00600.x.
    1. Laine M. L., Morré S. A., Murillo L. S., van Winkelhoff A. J., Peña A. S. CD14 and TLR4 gene polymorphisms in adult periodontitis. Journal of Dental Research. 2005;84(11):1042–1046. doi: 10.1177/154405910508401114.
    1. Schulz S., Zissler N., Altermann W., et al. Impact of genetic variants of CD14 and TLR4 on subgingival periodontopathogens. International Journal of Immunogenetics. 2008;35(6):457–464. doi: 10.1111/j.1744-313X.2008.00811.x.
    1. Holla L. I., Buckova D., Fassmann A., Halabala T., Vasku A., Vacha J. Promoter polymorphisms in the CD14 receptor gene and their potential association with the severity of chronic periodontitis. Journal of Medical Genetics. 2002;39(11):844–848. doi: 10.1136/jmg.39.11.844.
    1. Zheng J., Hou T., Gao L., et al. Association between CD14 gene polymorphism and periodontitis: a meta-analysis. Critical Reviews in Eukaryotic Gene Expression. 2013;23(2):115–123. doi: 10.1615/CritRevEukaryotGeneExpr.2013006952.
    1. Zhu G., Li C., Cao Z., Corbet E. F., Jin L. Vol. 39. Berlin, Germany:1985: Quintessence International; 2008. Toll-like receptors 2 and 4 gene polymorphisms in a Chinese population with periodontitis.
    1. Song G. G., Kim J. H., Lee Y. H. Toll-like receptor (TLR) and matrix metalloproteinase (MMP) polymorphisms and periodontitis susceptibility: a meta-analysis. Molecular Biology Reports. 2013;40(8):5129–5141. doi: 10.1007/s11033-013-2616-1.
    1. Chrzęszczyk D., Konopka T., Ziętek M. Polymorphisms of Toll-like receptor 4 as a risk factor for periodontitis: meta-analysis. Advances in Clinical and Experimental Medicine. 2015;24(6):1059–1070. doi: 10.17219/acem/47394.
    1. Sellers R. M., Payne J. B., Yu F., TD L. V., Walker C., Mikuls T. R. TLR4 Asp299Gly polymorphism may be protective against chronic periodontitis. Journal of Periodontal Research. 2016;51(2):203–211. doi: 10.1111/jre.12299.
    1. Griga T., Klein W., Epplen J. T., Hebler U., Stachon A., May B. CD14 expression on monocytes and soluble CD14 plasma levels in correlation to the promotor polymorphism of the endotoxin receptor CD14 gene in patients with inactive Crohn’s disease. Hepato-Gastroenterology. 2004;52:808–811.
    1. Reiner A. P., Lange E. M., Jenny N. S., et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(1):158–164. doi: 10.1161/ATVBAHA.112.300421.
    1. Zhang H. F., Zhong B. L., Zhu W. L., et al. CD14 C-260T gene polymorphism and ischemic heart disease susceptibility: a HuGE review and meta-analysis. Genetics in Medicine. 2009;11(6):403–408. doi: 10.1097/GIM.0b013e3181a16cb0.
    1. Nakada T. A., Takahashi W., Nakada E., Shimada T., Russell J. A., Walley K. R. Genetic polymorphisms in sepsis and cardiovascular disease: do similar risk genes suggest similar drug targets? Chest. 2019;155(6):1260–1271. doi: 10.1016/j.chest.2019.01.003.
    1. Porsch-Ozcürümez M., Hucke J., Westphal S., Hubácek J. A., Schmitz G., Luley C. Post-hoc analysis on the CD14 C(-260)T promoter polymorphism and coronary heart disease. Physiological Research. 2007;56(6):727–733.
    1. Karban A. S., Okazaki T., Panhuysen C. I., et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Human Molecular Genetics. 2004;13(1):35–45. doi: 10.1093/hmg/ddh008.
    1. Buwitt-Beckmann U., Heine H., Wiesmüller K. H., et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. The Journal of Biological Chemistry. 2006;281(14):9049–9057. doi: 10.1074/jbc.M512525200.
    1. Guven M., Ismailoglu Z., Batar B., et al. The effect of genetic polymorphisms of TLR2 and TLR4 in Turkish patients with coronary artery disease. Gene. 2015;558(1):99–102. doi: 10.1016/j.gene.2014.12.047.
    1. Hamann L., Gomma A., Schröder N. W., et al. A frequent Toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. Journal of Molecular Medicine. 2005;83(6):478–485. doi: 10.1007/s00109-005-0643-7.
    1. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. New England Journal of Medicine. 2002;347(3):185–192. doi: 10.1056/NEJMoa012673.
    1. Morange P. E., Tiret L., Saut N., et al. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: the PRIME study. European Journal of Human Genetics. 2004;12(12):1041–1049. doi: 10.1038/sj.ejhg.5201277.
    1. Wu B. W., Zhu J., Shi H. M., Jin B., Wen Z. C. Association between Toll-like receptor 4 Asp299Gly polymorphism and coronary heart disease susceptibility. Brazilian Journal of Medical and Biological Research. 2017;50(9, article e6306) doi: 10.1590/1414-431x20176306.
    1. Boekholdt S. M., Agema W. R., Peters R. J., et al. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003;107(19):2416–2421. doi: 10.1161/01.CIR.0000068311.40161.28.
    1. Beijk M. A., Boekholdt S. M., Rittersma S. Z., et al. Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. Pharmacogenetics and Genomics. 2010;20(9):544–552. doi: 10.1097/FPC.0b013e32833d7b29.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi